Regis‑TR

Regis‑TR
Name	Regis‑TR
Device type	Transcatheter renal neuromodulation system
Use	Treatment-resistant hypertension

Regis‑TR

Regis‑TR is a transcatheter renal neuromodulation system developed for treatment-resistant hypertension and related sympathetic overactivity disorders. The device was evaluated in multicenter trials and compared with alternative devices and pharmaceutical regimens in randomized studies, and has been discussed in regulatory submissions, guideline committees, and healthcare technology assessments.

Overview

Regis‑TR was developed amid renewed interest in device-based blood pressure interventions following early reports from trials such as SYMPLICITY HTN-3, SPYRAL HTN-OFF MED, RADIANCE-HTN SOLO and subsequent analyses by panels including the European Society of Hypertension and the American Heart Association. The program involved collaboration between interventional groups with experience from centers reporting outcomes in trials at institutions like Cleveland Clinic, Mayo Clinic, Imperial College London and vendors active in catheter-based therapies such as Medtronic, Boston Scientific, and Abbott Laboratories. Regulatory engagement included submissions oriented toward pathways used by the Food and Drug Administration and notified bodies under Medical Device Regulation (EU) 2017/745. Postmarket surveillance plans referenced frameworks from National Institute for Health and Care Excellence and databases such as MAUDE and European vigilance systems.

Technical Specifications

Regis‑TR is a catheter-based system combining an intravascular delivery catheter, electrode or ablation element, energy generator, and mapping software. The console integrates signal processing algorithms informed by electrophysiology techniques used in ablation systems by companies like Biosense Webster and mapping approaches similar to those in Carto platforms. Energy modalities explored in the program align with those used in interventional therapies such as radiofrequency ablation in atrial fibrillation and ultrasound ablation as applied in trials by groups at Stanford University and Mount Sinai. The catheter design drew on materials and engineering strategies common to vascular devices from suppliers like Terumo and Cook Medical. Procedural workflow referenced perioperative protocols practiced in catheterization laboratories at centers such as Johns Hopkins Hospital and Massachusetts General Hospital.

Development and Design

The design process for Regis‑TR involved preclinical research using models and methods from laboratories including National Institutes of Health intramural programs and academic translational units at University of Oxford and Karolinska Institutet. Investigators used histological assessment protocols analogous to those in experiments at Harvard Medical School and device safety testing consistent with standards from ISO committees and guidance from the European Medicines Agency. Early feasibility studies were structured similarly to first-in-human work reported by teams at University College London and technology transfer groups collaborating with industry partners similar to Philips spinouts. Engineering iterations incorporated feedback from interventional cardiology groups at Mount Sinai and vascular specialists at University of California, San Francisco.

Operational History

Clinical development included single-arm feasibility cohorts and randomized controlled trials performed across academic centers in North America, Europe, and Asia. Sites participating in device trials mirrored networks engaged in multicenter protocols like those of SPYRAL and RADIANCE and included leading hypertension clinics at University of Toronto, Charité – Universitätsmedizin Berlin, and Peking Union Medical College Hospital. Trial oversight involved data monitoring committees and steering committees structured as in landmark device studies overseen by agencies such as the FDA and European Commission expert panels. Comparative effectiveness work referenced health technology assessments by organizations like NICE and reimbursement discussions in systems such as Centers for Medicare & Medicaid Services.

Clinical Applications and Efficacy

Regis‑TR was evaluated for reduction in ambulatory and office blood pressure among patients with resistant or uncontrolled hypertension despite regimens that included agents recommended in guidelines from the European Society of Cardiology and the American College of Cardiology. Efficacy endpoints mirrored those used in trials such as SYMPLICITY HTN-3 and SPYRAL HTN-OFF MED, including change in daytime ambulatory systolic blood pressure and proportion achieving prespecified thresholds used in studies at institutions like Vanderbilt University Medical Center and University of Michigan. Subgroup analyses considered comorbid populations treated in specialty clinics for conditions seen at Stanford University Medical Center and Cleveland Clinic. Health outcomes modeling for cost-effectiveness took cues from published models used by IQVIA and academic health economists affiliated with London School of Economics and Harvard T.H. Chan School of Public Health.

Safety and Adverse Events

Safety assessment followed frameworks applied in device trials monitored by committees and reporting systems such as the Data Safety Monitoring Board model and postmarket vigilance similar to filings in the MAUDE database and European vigilance reports. Reported adverse events included access-site complications encountered in interventional programs at centers like Massachusetts General Hospital, transient renal artery changes analogous to those described in renal denervation literature from groups at Erasmus MC and Seoul National University Hospital, and device-related procedural events tracked in registries maintained by societies including the European Society of Cardiology and the Society for Cardiovascular Angiography and Interventions. Risk mitigation strategies referenced peri-procedural care pathways used in catheter-based therapies at institutions such as Johns Hopkins Hospital and UCSF Medical Center.

Category:Medical devices